

Ref: FOI/GS/ID 5226

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

28 March 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Sclerosis.

You asked:

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Brabio (glatiramer acetate)
Cladribine (Mavenclad)
Copaxone (glatiramer acetate)
Daclizumab (Zinbryta)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Ocrevus (Ocrelizumab)
Peginterferon beta-1a (Plegridy)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Others
Ampyra (Fampyra)

Trust response:

Aubagio (Teriflunomide) - 7 patients
Avonex (interferon beta-1a) - 3 patients
Betaferon (interferon beta-1b) - none

Brabio (Glatiramer acetate) - none
Cladribine (Mavenclad) - 5 patients
Copaxone (Glatiramer acetate) - 1 Patient
Daclizumab (Zinbryta) - none
Extavia (beta interferon-1b) - none
Gilenya (Fingolimod) - 1 patient
Lemtrada (Alemtuzumab) - 1 patient
Ocrevus (Ocrelizumab) none
Peginterferon beta-1a (Plegridy) - 3 patients
Rebif (beta interferon-1a) - none
Tecfidera (dimethyl fumarate) - 11 patients
Tysabri (Natalizumab) - none
Others - none
Ampyra (Fampyra) - none